TABLE 1.

Quantitative imaging parameters from DCE-CT and ¹⁸FDG-PET before and during treatment with cetuximab in 14 patients with squamous cell carcinoma of the head and neck

Patient	Fp	ve*	vp	PS	SUV*	Cellularity	Tumor
	(mL.min−1.100g−1)	(%)	(%)	(mL.min−1.100g−1)		(%)	localization, staging
Pretreatment
1	313.7	30.3	8.1	53.8	14.3	-	L, T2N0
2	378.6	39.2	12.0	59.7	16.8	-	OC, T2N0
3	157.2	15.4	16.0	37.7	10.6	-	OC, T2N0
4	366.5	60.5	13.7	81.9	11.4	-	OC, T1N0
5	73.9	41.8	15.3	28.6	9.9	-	OC, T1N0
6	136.1	30.9	11.1	69.2	13.4	-	OC,T4N0
7	278.0	36.4	15.5	47.3	8.8	-	L, T2N0
8	116.9	39.5	13.6	42.0	8.3	-	OC, T2N1
9	93.7	41.9	13.0	82.9	16.2	-	OC, T2N1
10	163.2	21.9	9.5	37.2	12.3	-	L, T2N0
11	72.7	29.1	9.2	38.1	7.4	-	OC, T2N0
12	286.6	49.8	5.6	40.9	28.9	-	OC, T3N0
13***	128.0	37.0	10.8	44.6	14.8	-	OC, T2N0
14	222.8	21.1	18.7	36.2	18.9	-	OC, T2N2b
m ± SD	199 ± 107	35 ± 12	12 ± 3.5	50 ± 17	14 ± 5.6	-
Post treatment
1	281.1	30.3	9.0	42.6	9.2	77
2	292.6	47.9	8.5	87.4	8.4	45
3	305.9	40.1	11.8	45.6	4.8	38
4	357.9	66.7	14.5	75.0	4.9	34
5	40.8	46.1	8.6	31.4	11.4	55
6	99.1	18.0	4.5	78.3	6.8	40
7	219.6	38.7	2.2	40.4	4.5	54
8	411.9	53.3	3.9	60.5	4.9	49
9	72.4	68.4	31.2	30.7	4.3	25
10	92.3	53.5	12.8	22.8	6.7	63
11	75.9	77.6	14.6	44.1	3.9	35
12	184.0	47.4	8.9	33.8	3.4	22
13***	131.2	46.1	9.9	60.7	6.0	26
14	359.2	33.7	13.7	53.7	8.3	36
m ± SD	209 ± 126	48 ± 16	11 ± 7.0	51 ± 20	6.3 ± 2.3	42.8± 15.5

^*Parameters with significant statistical differences between pretreatment and during treatment (p < 0.05)

^***PET/CT, Diffusion-weighted MR images and TICs are given inFigures 4 and 2.

F_p = blood flow; v_e = extracellular, extravascular fraction; v_p = fraction of vascular space; PS = transfer constant, L = larynx; OC = oral cavity